Seneschal Advisors
DGX icon

Seneschal Advisors’s Quest Diagnostics DGX Stock Holding History

Seneschal Advisors’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$700 Hold
3
– – ﹤0.01% 343
2026
Q2 		$636 Hold
3
– – ﹤0.01% 347
2026
Q1 		$588 Buy
3
+1
+50% +$194 ﹤0.01% 330
2025
Q4 		$348 Hold
2
– – ﹤0.01% 451
2025
Q3 		$382 Buy
+2
New +$355 ﹤0.01% 433

Other funds holding DGX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Seneschal Advisors's DGX Position: Q3 2026 in Review

Seneschal Advisors held its Quest Diagnostics (DGX) position steady in Q3 2026 at 3 shares worth $700. The position accounts for ﹤0.01% of the portfolio, ranked #343.

Seneschal Advisors first reported a position in DGX in Q3 2025 and has held it in 5 quarters since. 978 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

  • Seneschal Advisors held 3 shares of Quest Diagnostics worth $700 as of Q3 2026.
  • Seneschal Advisors left its Quest Diagnostics share count unchanged in Q3 2026.
  • Quest Diagnostics made up ﹤0.01% of Seneschal Advisors's portfolio in Q3 2026, its #343 holding.
  • Seneschal Advisors first reported a position in Quest Diagnostics in Q3 2025 and has held it in 5 quarters since.
  • 978 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on Seneschal Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.